April 18, 2024
FDA Grants De Novo Clearance to Scopio Labs’ AI-Powered Bone Marrow Pathology Application for Blood Disorders and Cancer
Scopio Labs, De Novo Clearance, FDA, Bone Marrow Pathology, AI, Blood Disorders, Cancer
Charles River Launches Initiative for Animal Testing Alternatives
Charles River, Animal Testing Alternatives, Program Launch, Non-Animal Testing, Drug Development
Fujifilm Diosynth’s Restructuring Plan May Leave 240 Employees Jobless
Fujifilm Diosynth, CDMO (Contract Development and Manufacturing Organization), Restructuring plan, Potential job loss, 240 staffers
MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion
MedinCell, AbbVie, Long-acting injectable, Development pact, $1.9 billion
Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development
Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals
Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis
Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures
Detailed PHOENIX Study Reveals Relyvrio’s Failure in ALS Treatment
Relyvrio, PHOENIX study, Amyotrophic Lateral Sclerosis (ALS), Trial failure, Amylyx Pharmaceuticals
Eli Lilly’s Zepbound Shows Promising Results in Reducing Sleep Apnea Severity in Pivotal Trials
Eli Lilly, Zepbound, Sleep Apnea, Obstructive Sleep Apnea (OSA), Pivotal Trials, Obesity, GLP-1 Receptor Agonist, Tirzepatide, CPAP, Weight Loss
Sanofi Downsizes IGM Antibody Deal, Reduces Oncology Focus
Sanofi, IGM Biosciences, antibody deal, oncology, downsizing, partnership
Sage Therapeutics’ Dalzanemdor Outcomes Amid Parkinson’s Miss
Sage Therapeutics Dalzanemdor Parkinson